Crinetics Pharmaceuticals to Announce Q3 2024 Financial Results on Nov 12, 2024

SAN DIEGO, Oct. 16, 2024 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) has announced that it will release its financial results for the third quarter of 2024 on Tuesday, November 12, after the market closes. Following the announcement, the company's management will conduct a conference call at 4:30 p.m. ET to discuss the financial results and provide a business update.

The conference call on November 12 at 4:30 p.m. ET can be accessed through the following dial-in numbers: Domestic: 1-800-579-2543 and International: 1-785-424-1789, using the Conference ID: CRNXQ3. Alternatively, participants can join the live webcast on the Events section of the Crinetics website. It is recommended to dial in or register for the webcast at least 15 minutes prior to the scheduled start time to avoid any delays. A recording of the webcast will be available on the Investor Relations section of the Crinetics website.

Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing innovative treatments for endocrine diseases and endocrine-related tumors. The company's lead development candidate, paltusotine, is an investigational, once-daily oral drug that targets somatostatin receptor type 2 (SST2). Paltusotine has completed Phase 3 clinical trials for the treatment of acromegaly and is currently in Phase 2 trials for managing carcinoid syndrome associated with neuroendocrine tumors.

Another promising candidate from Crinetics is atumelnant (CRN04894), an investigational, first-in-class oral ACTH antagonist. Atumelnant is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of Crinetics' drug candidates, including those in its pipeline, are orally delivered, small molecule new chemical entities. These candidates are the result of the company's internal drug discovery efforts and include additional programs focused on various endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity, and GPCR-targeted oncology indications.